Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -28.45% is 61% above its 2-year average of -73.33%, near the high end of its 2-year range (-149.07%–-21.22%).
As of the fiscal period ended Tuesday, June 30, 2026. 58.57% above its 12-month average of -68.67%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -28.45%.
RETURN ON EQUITY (ROE)
-28.45%
RETURN ON EQUITY (ROE) AVG TTM
-68.67%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+58.57%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-41.10%
median of 707 covered companies
CURRENT VS SECTOR MEDIAN
+30.78%
vs the sector median at left
Palvella Therapeutics, Inc.
Market Cap
$1.84B
Return on Equity (ROE)
-28.45%
TTM Avg
-68.67%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.84B
Return on Equity (ROE)
-8.14%
TTM Avg
-6.28%
3Y Avg
-6.47%
5Y Avg
-2.03%
Market Cap
$1.83B
Return on Equity (ROE)
N/A
TTM Avg
-157.29%
3Y Avg
-33.70%
5Y Avg
49.06%
Market Cap
$1.85B
Return on Equity (ROE)
4.88%
TTM Avg
4.47%
3Y Avg
6.79%
5Y Avg
5.89%
Market Cap
$1.82B
Return on Equity (ROE)
15.62%
TTM Avg
13.87%
3Y Avg
11.38%
5Y Avg
11.40%
Market Cap
$1.81B
Return on Equity (ROE)
-32.46%
TTM Avg
-24.39%
3Y Avg
-19.07%
5Y Avg
-12.85%
Market Cap
$1.81B
Return on Equity (ROE)
-8.95%
TTM Avg
-23.57%
3Y Avg
-73.07%
5Y Avg
-68.36%
Market Cap
$1.81B
Return on Equity (ROE)
-43.94%
TTM Avg
-43.41%
3Y Avg
-41.23%
5Y Avg
-29.16%
Market Cap
$1.80B
Return on Equity (ROE)
N/A
TTM Avg
36.48%
3Y Avg
36.48%
5Y Avg
36.48%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Palvella Therapeutics, Inc. (PVLA) | $1.84B | -28.45% | -68.67% | N/A | N/A |
| Azenta, Inc. (AZTA)vs › | $1.84B | -8.14% | -6.28% | -6.47% | -2.03% |
| Novavax, Inc. (NVAX)vs › | $1.83B | N/A | -157.29% | -33.70% | 49.06% |
| Astrana Health, Inc. (ASTH)vs › | $1.85B | 4.88% | 4.47% | 6.79% | 5.89% |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.82B | 15.62% | 13.87% | 11.38% | 11.40% |
| Xencor, Inc. (XNCR)vs › | $1.81B | -32.46% | -24.39% | -19.07% | -12.85% |
| Sarepta Therapeutics, Inc. (SRPT)vs › | $1.81B | -8.95% | -23.57% | -73.07% | -68.36% |
| Novocure Ltd (NVCR)vs › | $1.81B | -43.94% | -43.41% | -41.23% | -29.16% |
| Generate Biomedicines, Inc. (GENB)vs › | $1.80B | N/A | 36.48% | 36.48% | 36.48% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 12.01% | -4.52% | -16.89% | -11.36% |
ROE
-28.4%
ROA
-24.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -28.45% |
| 2026-03-31 | -21.22% |
| 2025-12-31 | -149.07% |
| 2025-09-30 | -85.19% |
| 2025-06-30 | -59.40% |
| 2025-03-31 | -41.53% |
| 2024-12-31 | -27.85% |
| 2024-09-30 | -111.06% |
| 2024-06-30 | -117.85% |
| 2023-12-31 | -91.72% |
